Go Deep
Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 25,899 | -0.1 | 0.06 | 0.05 | 415.80 |
| Oct 2026 | 25,930 | -0.1 | 0.06 | 0.05 | 382.65 |
| Oct 2026 | 23,580 | -0.1 | 0.05 | 0.05 | 331.86 |
| Oct 2026 | 23,588 | -0.1 | 0.05 | 0.05 | 323.32 |
| Oct 2026 | 23,602 | -0.1 | 0.05 | 0.05 | 307.39 |
| Oct 2026 | 23,610 | -0.1 | 0.04 | 0.05 | 298.27 |
Apimeds Pharmaceuticals US, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -20,173,129.0 | -35,059,852.0 | -1,155,292.0 | -1,781,255.0 |
| EPS | -11.8 | -22.6 | — | -1.4 |
Apimeds Pharmaceuticals US, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Net Profit | -6,001,137.0 | -1,389,990.0 | -777,694.0 | -668,666.0 | — |
| EPS | -5.5 | -1.2 | -0.7 | -0.6 | — |
Apimeds Pharmaceuticals US, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 164,183,736.0 | 13,057.0 | 422,076.0 | 6,171.0 | — |
| Total Liabilities | 10,835,909.0 | 1,371,178.0 | 390,207.0 | 719,777.0 | — |
| Total Equity | 153,347,827.0 | -1,358,121.0 | 31,869.0 | -713,606.0 | — |
Owes vs Owns
Apimeds Pharmaceuticals US, Inc. owed $0.17 for every $1 it owned in Jun 2026, down from $117 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.17× | 0.07× | 105× | 0.92× | 117× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Apimeds Pharmaceuticals US, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 2.2%Long-term investments 91.3%Other assets 6.3%
How it's funded — Dec 2025
Short-term debt 4.6%Payables 0.6%Other liabilities 1.3%Shareholders' equity 93.4%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 3.6 | 0.0 | 0.4 | 0.0 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 0.2 | 0.0 | 0.0 | 0.0 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 149.9 | 0.0 | 0.0 | 0.0 |
| Other assets | 10.4 | 0.0 | 0.0 | 0.0 |
| Liabilities & equity | ||||
| Short-term debt | 7.6 | 0.2 | 0.0 | 0.3 |
| Long-term debt | 0.1 | 0.3 | 0.3 | 0.4 |
| Payables | 0.9 | 0.6 | 0.1 | 0.0 |
| Other liabilities | 2.2 | 0.2 | 0.1 | 0.0 |
| Shareholders' equity | 153.3 | -1.4 | 0.0 | -0.7 |
| Net tangible assets | 153.3 | -1.4 | 0.0 | -0.7 |
Apimeds Pharmaceuticals US, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -8,925,777.0 | -733,526.0 | -627,790.0 | -448,167.0 | — |
| Investing Activities | -10,060,351.0 | 0.0 | 0.0 | 0.0 | — |
| Financing Activities | 20,619,327.0 | 326,500.0 | 1,032,100.0 | 282,900.0 | — |